Cargando…

Therapeutic targeting of CK2 in acute and chronic leukemias

CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buontempo, F, McCubrey, J A, Orsini, E, Ruzzene, M, Cappellini, A, Lonetti, A, Evangelisti, C, Chiarini, F, Barata, J T, Martelli, A M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770594/ https://www.ncbi.nlm.nih.gov/pubmed/28951560 http://dx.doi.org/10.1038/leu.2017.301

Ejemplares similares

PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors
por: Lonetti, Annalisa, et al.
Publicado: (2015)

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB
por: Buontempo, Francesca, et al.
Publicado: (2015)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
por: Martelli, Alberto M., et al.
Publicado: (2012)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2010)

The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias
por: Martelli, Alberto M., et al.
Publicado: (2020)

Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies
por: Martelli, Alberto M., et al.
Publicado: (2022)

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
por: Lonetti, Annalisa, et al.
Publicado: (2016)

The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
por: Martelli, Alberto M., et al.
Publicado: (2010)

Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2013)

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels
por: Bressanin, Daniela, et al.
Publicado: (2012)

Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics
por: Evangelisti, Cecilia, et al.
Publicado: (2014)

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
por: Chiarini, Francesca, et al.
Publicado: (2012)

B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?
por: Ratti, Stefano, et al.
Publicado: (2020)

The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia
por: Chiarini, Francesca, et al.
Publicado: (2020)

Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
por: Martelli, Alberto M., et al.
Publicado: (2023)

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines
por: Ultimo, Simona, et al.
Publicado: (2017)

The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response
por: Martelli, Alberto M., et al.
Publicado: (2019)

GSK-3β: A key regulator of breast cancer drug resistance
por: Martelli, Alberto M, et al.
Publicado: (2014)

Protein kinase CK2: a potential therapeutic target for diverse human diseases
por: Borgo, Christian, et al.
Publicado: (2021)

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia
por: Cani, Alice, et al.
Publicado: (2015)

Targeting CK2 in cancer: a valuable strategy or a waste of time?
por: Salvi, Mauro, et al.
Publicado: (2021)

Role of protein kinase CK2 in antitumor drug resistance
por: Borgo, Christian, et al.
Publicado: (2019)

The Cutting Edge: The Role of mTOR Signaling in Laminopathies
por: Chiarini, Francesca, et al.
Publicado: (2019)

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
por: Simioni, Carolina, et al.
Publicado: (2014)

Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells
por: Evangelisti, Camilla, et al.
Publicado: (2020)

The importance of negative determinants as modulators of CK2 targeting. The lesson of Akt2 S131
por: Vilardell, Jordi, et al.
Publicado: (2018)

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2016)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity
por: Steelman, Linda S., et al.
Publicado: (2011)

A novel DAG-dependent mechanism links PKCa and Cyclin B1 regulating cell cycle progression
por: Poli, Alessandro, et al.
Publicado: (2014)

Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB
por: Girardi, Cristina, et al.
Publicado: (2015)

Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specifc cell-permeable peptide inhibitor
por: Martins, Leila R., et al.
Publicado: (2013)

Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia
por: Perez, Dominique R., et al.
Publicado: (2016)

Recent progress in targeting cancer
por: Demidenko, Zoya N., et al.
Publicado: (2011)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells
por: Kreutzer, Jan N, et al.
Publicado: (2010)

Healthy CD4(+) T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia
por: Alameen, Ayman A.M., et al.
Publicado: (2016)

Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria‐related disorders
por: Evangelisti, Camilla, et al.
Publicado: (2016)

Phytol and Heptacosane Are Possible Tools to Overcome Multidrug Resistance in an In Vitro Model of Acute Myeloid Leukemia
por: Labbozzetta, Manuela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_21a3acr8au84uo19oa5u66es5c